Skip to main content
Glama

Startup Valuation MCP Server

Biotech Pipeline Valuation

valuation_biotech
Read-onlyIdempotent

Risk-adjusted biotech valuation: peak sales, decision-tree expected value, and full pipeline rNPV across drugs. Method selects the model. Use for pharma/drug pipelines; for hardware or deep tech use valuation_hardware. Parameters apply per method: peak_sales needs patient_population + penetration + price; decision_tree needs probabilities + terminal_value; pipeline needs drugs + discount_rate. Not for hardware or deep tech — for that use valuation_hardware. Only method is required; all other parameters are method-dependent, so supply those the selected method names and omit the rest (defaults apply where defined). Rate and decimal inputs are fractions (0.10 = 10%); probability and weight lists are in [0,1] and sum to 1. Returns value, method, inputs, assumptions, chapter, formula_number and calculation steps; pure arithmetic — no I/O and no external calls — rounded to 2 decimals, with no auth or rate limits. An unknown method, or a missing method-required parameter, returns an error instead of a value.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
drugsNoPipeline drugs: {name, peak_sales, probability, years_to_market, multiple(optional)}.
priceNoPrice per unit / treatment, currency units.
methodYesFormula to apply. Options: peak_sales = Peak = population × penetration × price × compliance.; decision_tree = EV = Π pᵢ × terminal value.; pipeline = V = Σ(peak sales × multiple × P_success) / (1+r)^n.
complianceNoCompliance / adherence rate as a decimal.
penetrationNoMarket penetration as a decimal (0.10 = 10%).
discount_rateNoDiscount rate as a decimal (0.12 = 12%).
probabilitiesNoProbability of each outcome or stage, each in [0,1]; the list must sum to 1 where it is exhaustive.
terminal_valueNoExpected exit / terminal value, currency units.
patient_populationNoTarget patient population treated per year.

Output Schema

TableJSON Schema
NameRequiredDescriptionDefault
errorNoError message when the call fails.
stepsNoIntermediate steps for traceability.
valueYesComputed valuation or metric.
inputsNoEcho of the normalised inputs used.
methodNoFormula / method name that produced the result.
chapterNoSource textbook chapter.
assumptionsNoModelling assumptions applied.
formula_numberNoSource textbook formula number (e.g. '3.1').

Schema Changelog

Changes observed during successful MCP inspections.

  1. First observed

TDQS

A4.2/5.0
Behavior3/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint, idempotentHint, non-destructive and non-open-world, so the safety profile is covered. The description still adds genuinely useful behavior beyond them: pure arithmetic with no I/O or external calls, 2-decimal rounding, no auth or rate limits, and error-not-value behavior on unknown method or missing required parameter. These are helpful but partly restate the closed-world safety model the annotations already imply.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

Front-loaded with purpose, then model selection, then per-method parameters, then units and return shape. Mostly efficient, but the hardware exclusion is stated twice ('for hardware or deep tech use valuation_hardware' and 'Not for hardware or deep tech — for that use valuation_hardware'), which is redundant.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a 9-parameter, method-dispatch calculator with an output schema, the description covers model selection, required vs method-dependent parameters, units/domain constraints (fractions, [0,1] summing probabilities), and error behavior. Nothing an agent needs to invoke it correctly is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% and the enum already spells out each formula, so the schema does the heavy lifting. The description adds real value by mapping which parameters each method consumes (peak_sales -> patient_population/penetration/price; decision_tree -> probabilities/terminal_value; pipeline -> drugs/discount_rate), but does not add syntax the schema lacks. Baseline 3 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb+resource ('Risk-adjusted biotech valuation') and immediately names the three selectable models (peak sales, decision tree, rNPV) it computes. It explicitly distinguishes itself from the sibling valuation_hardware by domain, so an agent can route without opening either schema.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Explicit when-to-use ('pharma/drug pipelines') and when-not ('not for hardware or deep tech'), naming the alternative tool valuation_hardware. It also states the selection rule ('Method selects the model') and that only method is required.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.